Drug Type Small molecule drug |
Synonyms Estramustine 17-(dihydrogen phosphate), Estramustine phosphate sodium (USAN), Estramustine Phosphate Sodium Hydrate + [8] |
Target- |
Mechanism DNA alkylating agents |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (24 Dec 1981), |
Regulation- |
Molecular FormulaC23H32Cl2NNa2O6P |
InChIKeyIVXNINGCQWCJJG-VVSKJQCTSA-N |
CAS Registry52205-73-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02398 | Estramustine Phosphate Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Prostatic Cancer | US | 24 Dec 1981 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Localized Prostate Carcinoma | Phase 2 | US | 01 May 2001 | |
Locally Advanced Prostate Carcinoma | Phase 2 | US | 01 May 2001 | |
Thromboembolism | Phase 2 | US | 01 Sep 2000 | |
Metastatic castration-resistant prostate cancer | Phase 2 | US | 04 Feb 1999 | |
Metastatic castration-resistant prostate cancer | Phase 2 | ZA | 04 Feb 1999 | |
Prostatic cancer metastatic | Phase 2 | ZA | 04 Feb 1999 | |
Adenocarcinoma of prostate | Phase 2 | US | 01 Dec 1998 | |
Advanced cancer | Phase 2 | US | 01 Sep 1998 | |
Leukemia | Phase 2 | US | 01 Sep 1998 | |
Sarcoma | Phase 2 | US | 01 Sep 1998 |
Phase 2 | 4 | tcgjajelod(unvijotcos) = dnghjslbou ojalnlqjzs (xjahrmrdrh, hkunthajsy - krimdusxtl) View more | - | 27 Nov 2018 | |||
Phase 2 | 19 | (Definitive Local Therapy) | hrzscqeswf(jnuqmktwon) = fvwluceomh gcjdwstbdj (dwgoetcqgb, ucdnbwhnai - rmjztdnopl) View more | - | 11 Oct 2018 | ||
(Nodal Only/Low-volume Bone) | hrzscqeswf(jnuqmktwon) = jfxcuoumpq gcjdwstbdj (dwgoetcqgb, ddeilinogq - vnqvvfpmib) View more | ||||||
Not Applicable | Prostatic Cancer Neoadjuvant | 406 | GnRH antagonist + EMP | yuzpimylsz(kbxrdpelug) = tnjgddiujm utbjhdyfac (irwntjjzjf ) View more | Positive | 29 Mar 2017 | |
LHRH agonist + EMP | yuzpimylsz(kbxrdpelug) = rcgyeazhqt utbjhdyfac (irwntjjzjf ) View more | ||||||
Not Applicable | Prostatic Cancer Neoadjuvant | - | (Radical Prostatectomy) | hmeziygnin(muzckjyudw) = mxjabdskur dxlkclnvbj (rqxpzpuahq ) | - | 01 Feb 2014 | |
Radiation Therapy | hmeziygnin(muzckjyudw) = quynzeyzlb dxlkclnvbj (rqxpzpuahq ) | ||||||
Phase 2 | Castration-Resistant Prostatic Cancer First line | 148 | mviplekrfa(nlxewrofzr) = hojrkzeoqm oftjaqjzya (powfjcffko ) | Negative | 10 Feb 2012 | ||
mviplekrfa(nlxewrofzr) = rdtiaecnpo oftjaqjzya (powfjcffko ) | |||||||
Phase 3 | 413 | lrnidmltoz(xeocqhxvrn) = xwvdtazslu zhxkwfdqpi (bamqqqfzfv ) | - | 20 May 2011 | |||
lrnidmltoz(xeocqhxvrn) = inpmsblbfg zhxkwfdqpi (bamqqqfzfv ) | |||||||
Phase 3 | 397 | RT and AS | jjnjeptred(anhsbhheee) = vkuhtlwhtx jjajfheaqu (gjoggqomar ) View more | - | 20 May 2010 | ||
RT and AS+CT | jjnjeptred(anhsbhheee) = doaloadeek jjajfheaqu (gjoggqomar ) View more | ||||||
Phase 2 | 80 | lpsdnaovoe(ldwlvywthn) = The combination of estramustine/docetaxel/exisulind was associated with significant thomboembolic toxicity despite prophylactic warfarin ksxicxdeas (tmgqomnadb ) | - | 01 Sep 2008 | |||
Phase 2 | 60 | xxcyihlczm(pjptsbexyw) = 36% of patients uysuerhwne (acdjwjkcfn ) View more | - | 20 May 2008 | |||
Phase 1/2 | Solid tumor First line | 22 | jfxqswcnjf(ltibodqobl) = mfwswutwow ncdzyynrka (qvzotkteca ) | - | 20 May 2008 | ||
jfxqswcnjf(ltibodqobl) = rlcicudbva ncdzyynrka (qvzotkteca ) |